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Lower urinary tract symptoms (LUTS) are preva-
lent among men. LUTS are divided into three
categories: storage, voiding, and postmicturition.
According to the definition by the International
Continence Society, storage LUTS are composed
of the symptoms of overactive bladder (OAB) and
urgency with or without urgency incontinence,
usually with frequency and nocturia.1 Storage
LUTS are often associated with bladder outlet ob-
struction due to benign prostate hyperplasia (BPH)
in men. The pathophysiology of male LUTS that
is suggestive of BPH is multifactorial. Thus, the
therapeutic target shifts from the prostate and use
of α-antagonists, 5-α-reductase inhibitors and sur-
gical intervention to the urinary bladder.2 Recent
investigations have shown that multiple pathways
are involved in bladder dysfunction. Therefore,
several novel strategies to treat BPH and LUTS are
briefly discussed.
Antimuscarinic Medication
Recent studies have demonstrated both the effec-
tiveness and safety of antimuscarinic drug and 
α-antagonist combinations, improving both uro-
dynamic and patient-reported outcomes in men
with LUTS and BPH.1–3 Anticholinergic drugs are
competitive antagonists of bladder muscarinic
receptors. During bladder filling, the drugs sup-
press involuntary detrusor contractions caused by
basal release of neuronal and urothelial acetyl-
choline. During the voiding phase, massive para-
sympathetic outflow and acetylcholine release
might overcome the effects of antimuscarinic med-
ication. A prospective randomized study demon-
strated that men with symptoms suggestive of both
BPH and OAB showed significant improvements
in LUTS with tolterodine extended release and
tamsulosin, an α-adrenergic antagonist, compared
with placebo, tolterodine extended release alone,
or tamsulosin alone.1 There is increasing evidence
to show that men with OAB and obstructive or
non-obstructive BPH can benefit from tolterodine
with or without α-blockers and are at low risk for
acute urinary retention, increased postvoid resid-
ual, or acute urinary tract infection.4,5
b3-adrenoreceptor Agonists
Real-time reverse transcription–polymerase chain
reaction analysis revealed the predominant ex-
pression of β3-adrenoreceptor (AR) mRNA in the
human detrusor muscle, which was 97% of total
β-ARs.6 Functional studies have demonstrated that
AR agonist-evoked relaxation is mediated pri-
marily by β3-ARs in human bladder tissue.7,8
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NEWS AND PERSPECTIVES
In vivo studies indicate that β3-AR agonists in-
crease bladder capacity with no change in mic-
turition pressure and residual volume, indicating
that β3-AR agonists are useful in storage symp-
toms secondary to obstructed bladder.9
Purinoceptor Antagonists
Adenosine triphosphate (ATP) can be released by
distension of the bladder and activation of the
micturition reflex. The ATP receptor, P2X3, is ex-
pressed on small diameter primary sensory neu-
rons and urothelium, and analysis of bladder
biopsies from patients with detrusor overactivity
revealed increased P2X3 receptors in these pa-
tients. Given the emergent roles of ATP, modula-
tion of P2X receptor activity has been thought to
be a potential target of therapeutic intervention
in LUTS. Activation of recombinant and native
P2X3 and P2X2/3 receptors was inhibited by sub-
micromolar concentrations of A-317491, and ef-
ficacy was demonstrated in several models of
chronic inflammatory and neuropathic pain. 
Lu et al recently demonstrated that A-317491 in-
hibits non-micturition bladder contractions with-
out affecting voiding contractility in a rat spinal
cord injury model.10 Improving the pharmacoki-
netics and bioavailability of both of these poten-
tial drugs will increase the treatment potential.
Vanilloid Receptors
The role of vanilloid receptors such as transient
receptor potential vanilloid (TRPV-1) in the patho-
physiology of neurogenic or idiopathic detrusor
overactivity has been recognized. C-fiber input
plays an important role in the generation of the
urgency sensation. Resiniferatoxin (RTX) is the
sole compound with a desensitizing effect suitable
for human use. Furthermore, bladder instillation
of vanilloid agents, such as capsaicin and RTX,
resulted in increased bladder capacity and de-
creased urge incontinence. Finally, bladder de-
sensitization by RTX was useful in the treatment
of patients with urinary urgency, particularly if
refractory to the anticholinergic agents, and may
also improve BPH-associated storage symptoms.11
Botulinum Toxins
Botulinum neurotoxin type-A (BoNT-A) induces
prostate cell apoptosis and decreases cell prolifer-
ation in a dose-dependent manner. Some animal
studies have shown that relaxation of the prostate
is due to α1-adrenergic receptor downregulation
of stromal smooth muscle cells and impaired re-
lease of norepinephrine from adrenergic nerve
endings.12,13 BoNT-A has been proven to be effec-
tive in reducing detrusor overactivity, and the 
efficacy of BoNT-A on LUTS due to BPH has also
been demonstrated. Kuo evaluated the effective-
ness of BoNT-A injection into the prostates of BPH
patients and reported that all patients experienced
improvements in spontaneous voiding.14 Further
information, including dosing, effect duration,
effect on prostate size, prostate-specific antigen,
and repeated injections, are required in future
evaluations.
Endothelin Antagonists
Endothelins have a direct contractile effect on
prostatic smooth muscle cells, may enhance α1-
receptor-mediated smooth muscle contraction, and
stimulate cell proliferation. Endothelin-1 (ET-1)
is an endogenous vasoactive peptide that binds
two receptor subtypes, the endothelin-A (ETA) and
endothelin-B (ETB) receptors. ET-1 can directly
activate C-fiber afferent nerves in the bladder, and
suppression of ETA receptors might be effective
for the treatment of detrusor overactivity by reduc-
ing activation of C-fiber afferent pathways. Bladder
hypertrophy is common in various pathologies
of the bladder or its outlets, such as BPH or neu-
ropathic bladder, including spinal cord injury
(SCI).15 In vitro studies with smooth muscle cells
obtained from obstructed rabbit bladders have
shown that endothelin antagonists inhibit smooth
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muscle cell proliferation.16 Taken together, en-
dothelin antagonists are effective against OAB.
Phosphodiesterase-5 Inhibitors
The association between LUTS and erectile dys-
function (ED) has been increasingly recognized
and investigated. ED, ejaculatory disorders, and
pain during intercourse are correlated with the
severity of LUTS, and several studies have re-
ported LUTS to be an independent risk factor for
the development of ED.17,18 Several pathophysi-
ologies common to LUTS and ED, such as age,
atherosclerosis-induced vascular insufficiency in
the bladder and corpora, and autonomic nervous
system hyperactivity, have been reported and are
potentially mediated by nitric oxide pathways. 
In addition, there are significant amounts of phos-
phodiesterase types 4 and 5 in the transition zone
of the prostate. Given the potential common 
etiology of LUTS and ED, phosphodiesterase-5
inhibitors and α-blockers are advantageous to
both diseases.
Conclusion
The available reports regarding these novel med-
ical therapies for LUTS in men demonstrated
them to be effective. In addition, other pharma-
ceutical therapies, including angiotensin recep-
tor antagonists, vitamin D3 receptor analogs and
rho-kinase inhibitors, that are associated with
blocking prostate growth and relieving LUTS are
under investigation.
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